Spero Therapeutics, Inc.SPRONASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank70
3Y CAGR-13.1%
5Y CAGR+2.2%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-13.1%/yr
vs +29.7%/yr prior
5Y CAGR
+2.2%/yr
Recent deceleration
Acceleration
-42.8pp
Decelerating
Percentile
P70
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$23.93M+1.0%
2024$23.70M-7.2%
2023$25.55M-30.0%
2022$36.48M-12.5%
2021$41.70M+94.5%
2020$21.44M+37.5%
2019$15.59M+21.0%
2018$12.89M+18.9%
2017$10.84M+50.1%
2016$7.22M-